Consistent with the reports discussed above that MTF2 has oncogenic activity in HCC [20], hepatocellular carcinoma patients with higher levels of MTF2 expression showed reduced survival rates compared to “MTF2-low” patients (Figure 4E). This evidence concerns the gene MTF2 and hepatocellular carcinoma.